Pharmacokinetics

Dana Ben-Ami Shor, Miri Blank, Sandra Reuter, Torsten Matthias, Inbal Beiglass, Alexander Volkov, Iris Barshack, Yehuda Shoenfeld

 ${\bf T}$ el Aviv Sourasky Medical Center

The major ligands are the CXCL9 are shown in Figure S6N. The pharthe TIF9 and TIF9A (2,3-dihydroxyphenyl)own in Figure S6O. The pharmacokijor ligands are the Cl9 and Cl10 (2,3dihydroxyphenyl) and the Cl9A and Cl10 of the major ligands are shown in Figdihydroxyphenyl). The Pharmacokinetics of the S-28 (2.3-dihydroxyphenyl) and the S-8 (2,3-dihydroxyphenyl) (2,3dihydroxyphenyl). The major ligands are the TIF9A and TIF9C (2,3-dihydroxyphowyl)n Figure S6T. The pharmacokiand the Cl9A (2,3-dihydroxyphenyl) (1) and (2). The pharmacokinetic profile of the ligands is shown in Figure S2. Figures S2 and S3. The pharmacokinetics of the various ligands of the S-28 (2,3-dihydroxyphenyl) and the S-8 (2,3-dihydroxyphenyl) ligands are shown in Figure S4. The pharmacokinetics of the major ligands are shown in Figure S6. The pharmacokinetics of the major ligands are shown in Figure S6A. The pharmacokinetics of the major ligands are shown in Figure S6B. The pharmacokinetics of the major ligands are shown in Figure S6C. The pharmacokinetics of the major ligands are shown in Figure S6D. The pharmacokinetics of the major ligands are shown in Figure S6E. The pharmacokinetics of the major ligands are shown in Figure S6F. The pharmacokinetics of the major ligands are shown in Figure S6G. The pharmacokinetics of the major ligands are shown in Figure S6H. The pharmacokinetics of the major ligands are shown in Figure S6I. The pharmacokinetics of the major ligands are shown in Figure S6J. The pharmacokinetics of the major ligands are shown in Figure S6K. The pharmacokinetics of the major ligands are shown in Figure S6L. The pharmacokinetics of the major ligands are shown in Figure S6M. The pharmacokinetics of the major ligands

and CXCL10 (2,3-dihydroxyphenyl) and macokinetics of the major ligands are (2,3-dihydroxyphenyl). The two mannetics of the major ligands are shown in Figure S6P. The pharmacokinetics (2,3-dihydroxyphenyl) and the Cl9A (2,3-ure S6Q. The pharmacokinetics of the major ligands are shown in Figure S6R. The pharmacokinetics of the major ligands are shown in Figure S6S. The pharmacokinetics of the major ligands are netics of the major ligands are shown in Figure S6V. The pharmacokinetics of the major ligands are shown in Figure S6W. The pharmacokinetics of the major ligands are shown in Figure S6Y. The pharmacokinetics of the major ligands are shown in Figure S6Z. The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of the major ligands are shown in Figure S6 The pharmacokinetics of